Psilocybin for Treatment-Resistant Depression
Center of Excellence on Mood Disorders is taking part in a worldwide multi-center study investigating the effects of psilocybin in treatment-resistant depression. The study is sponsored by COMPASS Pathways and listed on clinicaltrials.gov.
The study will analyze the effects of a single administration of psilocybin at three doses (1mg, 10mg, 25mg) in 216 patients. All patients on antidepressants must taper off them within 3-6 weeks prior to baseline (the study team will manage this). The study includes 13-16 visits, two of which can be done remotely, over a 15-18 week period. A specially trained study therapist will support every participant before, during and after the psilocybin session.